Cargando…
Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients
BACKGROUND: Acute graft-versus-host disease (aGVHD), a potentially life-threatening complication of hematopoietic stem cell transplantation (HSCT), often occurs within 100 days of HSCT. While steroids are typically used as first-line treatment, there is no consensus on second-line steroid-refractory...
Autores principales: | Grabner, Michael, Strati, Eric, Sandman, Karen, Forsythe, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390991/ https://www.ncbi.nlm.nih.gov/pubmed/33908282 http://dx.doi.org/10.18553/jmcp.2021.27.5.607 |
Ejemplares similares
-
Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons
por: Tremblay, Gabriel, et al.
Publicado: (2021) -
Intramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
por: Bilgin, Aynur Uğur, et al.
Publicado: (2012) -
Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease Using Commercial Mesenchymal Stem Cell Products
por: Murata, Makoto, et al.
Publicado: (2021) -
Murine Models of Steroid Refractory Graft-versus-Host Disease
por: Toubai, Tomomi, et al.
Publicado: (2018) -
What Does the Economic Burden of Acute Myeloid Leukemia Treatment Look Like for the Next Decade? An Analysis of Key Findings, Challenges and Recommendations
por: Forsythe, Anna, et al.
Publicado: (2021)